<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0601210382
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rexofil
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        136.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rexofil&trade; contains the active substance tadalafil which belongs to a group of<br />medicines called phosphodiesterase type 5 inhibitors.<br />Rexofil&trade; 5 mg is used to treat adult men with:<br />- erectile dysfunction. This is when a man cannot get, or keep a hard, erect penis<br />suitable for sexual activity. Rexofil&trade; has been shown to significantly improve the<br />ability of obtaining a hard erect penis suitable for sexual activity. Following sexual<br />stimulation Rexofil&trade; works by helping the blood vessels in your penis to relax,<br />allowing the flow of blood into your penis. The result of this is improved erectile<br />function. Rexofil&trade; will not help you if you do not have erectile dysfunction. It is<br />important to note that Rexofil&trade; for the treatment of erectile dysfunction does not<br />work if there is no sexual stimulation. You and your partner will need to engage in<br />foreplay, just as you would if you were not taking a medicine for erectile<br />dysfunction.<br />- urinary symptoms associated with a common condition called benign prostatic<br />hyperplasia. This is when the prostate gland gets bigger with age. Symptoms include<br />difficulty in starting to pass water, a feeling of not completely emptying the bladder<br />and a more frequent need to pass water even at night. Rexofil&trade; improves blood flow<br />to, and relaxes the muscles of, the prostate and bladder which may reduce symptoms<br />of benign prostatic hyperplasia. Rexofil&trade; has been shown to improve these urinary<br />symptoms as early as 1-2 weeks after starting treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- are allergic to tadalafil or any of the other ingredients of this medicine<br />(listed in section 6).<br />- are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite.<br />This is a group of medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris<br />(&ldquo;chest pain&rdquo;). Rexofil&trade; has been shown to increase the effects of these medicines.<br />If you are taking any form of nitrate or are unsure tell your doctor.<br />- have serious heart disease or recently had a heart attack within the last 90 days.<br />- recently had a stroke within the last 6 months.<br />- have low blood pressure or uncontrolled high blood pressure.<br />- ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy<br />(NAION), a condition described as &ldquo;stroke of the eye&rdquo;.<br />- are taking riociguat. This drug is used to treat pulmonary arterial hypertension<br />(i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary<br />hypertension (i.e., high blood pressure in the lungs secondary to blood clots).<br />PDE5 inhibitors, such as Rexofil&trade;, have been shown to increase the hypotensive<br />effects of this medicine. If you are taking riociguat or are unsure tell your doctor.<br />Warnings and precautions<br />Talk to your doctor before taking Rexofil&trade;.<br />Be aware that sexual activity carries a possible risk to patients with heart disease<br />because it puts an extra strain on your heart. If you have a heart problem you should<br />tell your doctor.<br />Since benign prostatic hyperplasia and prostate cancer may have the same<br />symptoms, your doctor will check you for prostate cancer before starting treatment<br />with Rexofil&trade; for benign prostatic hyperplasia. Rexofil&trade; does not treat prostate<br />cancer.<br />Before taking the tablets, tell your doctor if you have:<br />- sickle cell anaemia (an abnormality of red blood cells).<br />- multiple myeloma (cancer of the bone marrow).<br />- leukaemia (cancer of the blood cells).<br />- any deformation of your penis.<br />- a serious liver problem.<br />- a severe kidney problem.<br />It is not known if Rexofil&trade; is effective in patients who have had:<br />- pelvic surgery.<br />- removal of all or part of the prostate gland in which nerves of the prostate are cut<br />(radical non- nerve-sparing prostatectomy).<br />If you experience sudden decrease or loss of vision, stop taking Rexofil&trade; and<br />contact your doctor immediately.<br />Decreased or sudden hearing loss has been noted in some patients taking tadalafil.<br />Although it is not known if the event is directly related to tadalafil, if you experience<br />decreased or sudden hearing loss, stop taking Rexofil&trade; and contact your doctor<br />immediately.<br />Rexofil&trade; is not intended for use by women.<br />Children and adolescents<br />Rexofil&trade; is not intended for use by children and adolescents under the age of 18.<br />Other medicines and Rexofil&trade;<br />Tell your doctor if you are taking, have recently taken or might take any other<br />medicines<br />Do not take Rexofil&trade; if you are already taking nitrates.<br />Some medicines may be affected by Rexofil&trade; or they may affect how well<br />Rexofil&trade; will work. Tell your doctor or pharmacist if you are already taking:<br />- an alpha blocker (used to treat high blood pressure or urinary symptoms associated<br />with benign prostatic hyperplasia).<br />- other medicines to treat high blood pressure.<br />- riociguat.<br />- a 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).<br />- medicines such as ketoconazole tablets (to treat fungal infections) and protease<br />inhibitors for treatment of AIDS or HIV infection.<br />- phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).<br />- rifampicin, erythromycin , clarithromycin or itraconazole.<br />- other treatments for erectile dysfunction.<br />Rexofil&trade; with drink and alcohol<br />Information on the effect of alcohol is in section 3. Grapefruit juice may affect how<br />well Rexofil&trade; will work and should be taken with caution. Talk to your doctor for<br />further information.<br />Fertility<br />When dogs were treated there was reduced sperm development in the testes.<br />A reduction in sperm was seen in some men. These effects are unlikely to lead to a<br />lack of fertility.<br />Driving and using machines<br />Some men taking Rexofil&trade; in clinical studies have reported dizziness.<br />Check carefully how you react to the tablets before driving or using machines.<br />Rexofil&trade; contains lactose:<br />If you have an intolerance to some sugars, contact your doctor before taking this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your<br />doctor or pharmacist if you are not sure.<br />Rexofil&trade; tablets are for oral use in men only. Swallow the tablet whole with some<br />water. The tablets can be taken with or without food.<br />Drinking alcohol may temporarily lower your blood pressure. If you have taken or<br />are planning to take Rexofil&trade;, avoid excessive drinking (blood alcohol level of<br />0.08% or greater), since this may increase the risk of dizziness when standing up.<br />For the treatment of erectile dysfunction<br />The recommended dose is one 5 mg tablet taken once a day at approximately the<br />same time of the day. Your doctor may adjust the dose to 2.5 mg based on your<br />response to Rexofil&trade;.<br />Do not take Rexofil&trade; more than once a day.</p><p>When taken once a day Rexofil&trade; allows you to obtain an erection, when sexually<br />stimulated, at any time point during the 24 hours of the day. Once a day dosing of<br />Rexofil&trade; may be useful to men who anticipate having sexual activity two or more<br />times per week.<br />It is important to note that Rexofil&trade; does not work if there is no sexual stimulation.<br />You and your partner will need to engage in foreplay, just as you would if you were<br />not taking a medicine for erectile dysfunction.<br />Drinking alcohol may affect your ability to get an erection.<br />For the treatment benign prostatic hyperplasia<br />The dose is one 5 mg tablet taken once a day at approximately the same time of the<br />day. If you have benign prostatic hyperplasia and erectile dysfunction, the dose<br />remains one 5 mg tablet taken once a day.<br />Do not take Rexofil&trade; more than once a day.<br />If you take more Rexofil&trade; than you should<br />Contact your doctor. You may experience side effects described in section 4.<br />If you forget to take Rexofil&trade;<br />Take your dose as soon as you remember but do not take a double dose to make up for a<br />forgotten tablet. You should not take Rexofil&trade; more than once a day.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them. These effects are normally mild to moderate in nature.<br />If you experience any of the following side effects stop using the medicine and<br />seek medical help immediately:<br />- allergic reactions including rashes (frequency uncommon).<br />- chest pain - do not use nitrates but seek immediate medical assistance<br />(frequency uncommon).<br />- priapism, a prolonged and possibly painful erection after taking Rexofil&trade;<br />(frequency rare). If you have such an erection, which lasts continuously for more than<br />4 hours you should contact a doctor immediately.<br />- sudden loss of vision (frequency rare).<br />Other side effects have been reported:<br />Common (seen in 1 to 10 in every 100 patients)<br />- headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal<br />congestion, and indigestion.<br />Uncommon (seen in 1 to 10 in every 1,000 patients)<br />- dizziness, stomach ache, feeling sick, being sick (vomiting), reflux, blurred vision,<br />eye pain, difficulty in breathing, presence of blood in urine, prolonged erection,<br />pounding heartbeat sensation, a fast heart rate, high blood pressure, low blood<br />pressure, nose bleeds, ringing in the ears, swelling of the hands, feet or ankles and<br />feeling tired.<br />Rare (seen in 1 to 10 in every 10,000 patients)<br />- fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden<br />decrease or loss of hearing, hives (itchy red welts on the surface of the skin), penile<br />bleeding, presence of blood in semen and increased sweating.<br />Heart attack and stroke have also been reported rarely in men taking Rexofil&trade;.<br />Most of these men had known heart problems before taking this medicine.<br />Partial, temporary, or permanent decrease or loss of vision in one or both eyes has<br />been rarely reported.<br />Some additional rare side effects have been reported in men taking Rexofil&trade;<br />that were not seen in clinical trials.<br />These include:<br />- migraine, swelling of the face, serious allergic reaction which causes swelling of the<br />face or throat, serious skin rashes, some disorders affecting blood flow to the eyes,<br />irregular heartbeats, angina and sudden cardiac death.<br />The side effect dizziness has been reported more frequently in men over 75 years of<br />age taking Rexofil&trade;. Diarrhoea has been reported more frequently in men over 65<br />years of age taking Rexofil&trade;.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any<br />possible side effects not listed in this leaflet. By reporting side effects you can help<br />provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the carton after<br />&ldquo;EXP&rdquo;.<br />&bull; Store in the original package in order to protect from moisture.<br />&bull; Do not store above 30 &deg;C<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will<br />help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Rexofil&trade; contains<br />- The active substance is tadalafil.<br />Each film coated tablet contains 5 mg of tadalafil.<br />- The other ingredients are:<br />Lactose Monohydrate, Hydroxypropyl Cellulose, Croscarmellose Sodium, Sodium<br />Lauryl Sulphate, Microcrystalline cellulose, Magnesium Stearate, Hypromellose,<br />Titanium dioxide, Triacetin, Yellow iron oxide-non irradiated and Talc.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Rexofil™ looks like and contents of the pack
Rexofil™ 5 mg is a light yellow colored, almond shaped, film coated tablet,
debossed with "JP" on one side and "201" on the other side.
Rexofil™ 5 mg is available in blister packs containing 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222<br />Website: www.jamjoompharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11-2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>۱. ما ھو عقار ریكسوفیل<br />على المادة الفعّالة تادالافیل التي تنتمي إلى مجموعة من الأدویة تُسمى مثبطات إنزیم &trade; یحتوي عقار ریكسوفیل<br />الفوسفودایستریز من النوع الخامس.<br />٥ ملجم لعلاج الرجال البالغین في حالات: &trade; یستخدم عقار ریكسوفیل<br />- ضعف الانتصاب. وھذه الحالة تحدث عندما لا یستطیع الرجل الوصول إلى الانتصاب أو الحفاظ علیھ<br />والوصول إلى انتصاب كامل وثابت للعضو الذكري یمكن المریض من ممارسة النشاط الجنسي. قد أظھر عقار<br />تحسنًا ملحوظًا في القدرة على الحصول على قضیب منتصب ثابت ومناسب للنشاط الجنسي. &trade; ریكسوفیل<br />بعد التحفیز الجنسي عن طریق المساعدة على إرخاء الأوعیة الدمویة في العضو &trade; یعمل عقار ریكسوفیل<br />إذا لم &trade; الذكري مما یسمح بتدفق الدم إلیھ. ویؤدي ھذا إلى تحسن عملیة الانتصاب. لن یساعدك عقار ریكسوفیل<br />تكن تُعاني من ضعف الانتصاب.<br />لن یكون فعالًا إذا لم یتم التحفیز جنسیًا أولاً. ستحتاج أنت &trade; من المھم الوضع في الاعتبار أن عقار ریكسوفیل<br />وزوجتك إلى ممارسة المداعبة أولاً كما كنت تفعل في حالة عدم تناولك دواء لعلاج ضعف الانتصاب.<br />- الأعراض البولیة المرتبطة بحالة شائعة تسمى تضخم البروستاتا الحمید. و یحدث ھذا عندما تصبح غدة<br />البروستاتا أكبر مع تقدم العمر. تتضمن الأعراض صعوبة في بدء التبول ، شعور بعدم إفراغ المثانة تمامًا ، و<br />على تحسین تدفق الدم إلى عضلات &trade; حاجة أكثر تواترا إلى التبول حتى في اللیل. یعمل عقار ریكسوفیل<br />یحسن ھذه &trade; البروستاتا والمثانة ، مما یخفف من أعراض تضخم البروستاتا الحمید. لقد ثبت أن عقار ریكسوفیل<br />۲ أسبوع بعد بدء العلاج. - الأعراض البولیة في غضون ۱<br />&trade;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- إذا كنت تعاني من حساسیة تجاه تادالافیل أو تجاه أي مكون من المكونات الأخرى الداخلة في تركیب ھذا<br />.( الدواء (المدرجة في القسم رقم ٦<br />- إذا كنت تستخدم أي تركیبة من تركیبات النترات العضویة أو تتناول أدویة تحتوي على أكسید النیتریك مثل<br />أمیل نتریت. تُستخدَم ھذه المجموعة من الأدویة (النترات) لعلاج الذبحة الصدریة (ألم بالصدر). یُؤدي عقار<br />إلى زیادة تأثیرات ھذه الأدویة. إذا كنت تتناول أي شكل من أشكال النترات أو لم تكن متأكدًا مما &trade; ریكسوفیل<br />إذا كنت تتناولھا فاستشر طبیبك.<br />- إذا كنت تعاني من مرض خطیر بالقلب أو قد عانیت مؤخرًا من نوبة قلبیة خلال فترة ال ۹۰ یوم الماضیة.<br />- إذا أصبت مؤخرًا بسكتة دماغیة خلال فترة ال ٦ أشھر الماضیة.<br />- إذا كنت تعاني من انخفاض أو ارتفاع لا یمكن التحكم بھ في ضغط الدَّم.<br />- إذا كنت قد عانیت من قبل من فُقدان للرؤیة بسبب الاعتلال العصبي البصري الأمامي لنقص الترویة<br />وھي حالة تعرف ب &quot;جلطة العین&quot;. ،(NAION)<br />- إذا كنت تتناول عقار ریوسیجوات. یستخدم لعلاج فرط ضغط الدم الرئوي (أي ارتفاع ضغط الدم في الرئتین)<br />وفرط ضغط الدم الرئوي الناجم عن الانصمام الخثاري المزمن (على سبیل المثال ارتفاع ضغط الدم في الرئتین<br />الناجم عن تكون جلطات دمویة). أثبتت الدراسات أن مثبطات إنزیم الفوسفودایستریز من النوع الخامس<br />تزید الآثار الخافضة لضغط الدم لھذا الدواء. إذا كنت تتناول عقار &trade; مثل عقار ریكسوفیل (PDE5)<br />ریوسیجوات أو لم تكن متأكدًا مما إذا كنت تتناولھا فاستشر طبیبك.<br />تحذیرات واحتیاطات<br />.&trade; تحدث إلى طبیبك قبل تناول عقار ریكسوفیل<br />یُرجي العلم بأن النشاط الجنسي یشكل خطرًا محتملًا على المرضى الذین یعانون من مرض بالقلب حیث إنھ<br />ا على القلب. أخبر طبیبك إذا كنت تعاني من أیة مشاكل بالقلب. 􀌒 یشكل عبئًا إضافی<br />نظرًا لأن تضخم البروستاتا الحمید وسرطان البروستاتا قد یكون لھما نفس الأعراض ، فسیقوم طبیبك بالتحقق<br />لتضخم البروستاتا الحمید. عقار &trade; من سرطان البروستاتا قبل البدء في العلاج باستخدام عقار ریكسوفیل<br />لا یعالج سرطان البروستاتا. &trade; ریكسوفی</p><p>أخبر طبیبك قبل تناول الأقراص في الحالات الآتیة:<br />- إذا كنت تعاني من فقر الدم المنجلي (اضطراب في خلایا الدم الحمراء).<br />- إذ كنت تعاني من الورم النخاعي المتعدد (سرطان النخاع العظمي).<br />- إذا كنت تعاني من لوكیمیا (سرطان بخلایا الدَّم).<br />- إذا كنت تعاني من أي تشوه في العضو الذكري.<br />- إذا كنت تعاني من اضطراب حاد بالكبد.<br />- إذا كنت تعاني من اضطراب حاد بالكلى.<br />فعالًا في المرضى الذین خضعوا للعملیات التالیة: &trade; من غیر المعروف ما إذا كان عقار ریكسوفیل<br />- جراحة بمنطقة الحوض.<br />- عملیة إزالة كل أو جزء من غدة البروستاتا حیث یتم قطع أعصاب البروستاتا<br />(استئصال البروستاتا الجذري غیر العصبي)<br />واتصل بطبیبك فورًا. &trade; إذا كنت تُعاني من ضعف أو فقدان مفاجئ للرؤیة فتوقف عن تناوُل عقار ریكسوفیل<br />تمت ملاحظة انخفاض أو ضعف السمع المفاجئ في بعض المرضى الذین یستخدمون عقار یحتوي على مادة<br />واتصل بطبیبك &trade; تادالافیل. وإذا تعرضت لضعف أو فقدان مفاجئ للسمع فتوقف عن تناوُل عقار ریكسوفیل<br />&trade; فورًا على الرغم من أنھ غیر المعروف ما إذا كانت ھذه الآثار مرتبطة بشكل مباشر بتناول عقار ریكسوفیل<br />أم لا.<br />غیر مخصص للإستخدام بواسطة النساء. &trade; عقار ریكسوفیل<br />المرضى من الأطفال والمراھقین<br />غیر مخصص للإستخدام من قبل الأطفال والمراھقین الذین تقل أعمارھم عن ۱۸ سنة. &trade; عقار ریكسوفیل<br />&trade; تناول أدویة أخرى مع عقار ریكسوفیل<br />یُرجى إبلاغ طبیبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة أخرى.<br />إذا كنت بالفعل تتناول أدویة النترات. &trade; لا تتناول عقار ریكسوفیل<br />أو قد تُؤثر على فعالیة ھذا العقار. أخبر طبیبك أو الصیدلي إذا &trade; قد تتأثر فعالیة بعض الأدویة بعقار ریكسوفیل<br />كنت بالفعل تتناول أي من الأدویة التالیة:<br />- حاصرات ألفا (وھو دواء یستخدم لعلاج ارتفاع ضغط الدم أو الأعراض البولیة المصحوبة بمرض تضخم<br />البروستاتا الحمید).<br />- أدویة أخرى تستخدم لعلاج ارتفاع ضغط الدم.<br />- عقار ریوسیجوات.<br />- مثبط الإنزیم المختزل &quot;أ ٥-ألفا&quot; (یستخدم لعلاج تضخم البروستاتا الحمید).<br />- أدویة مثل أقراص كیتوكونازول (یستخدم لعلاج الالتھابات الفطریة) ومثبطات البروتیاز لعلاج مرض الإیدز<br />أو عدوى فیروس نقص المناعة البشریة.<br />- فینوباربیتال، فینیتوین و كربامازِیبین (أدویة تستخدم لعلاج التشنجات).<br />- ریفامبیسین، اریثرومیسین، كلاریثرومایسین أو إیتراكونازول.<br />- أدویة أخرى لعلاج ضعف الانتصاب.<br />مع المشروبات والكحولیات &trade; تناوُل عقار ریكسوفیل<br />تتوفر معلومات عن تأثیر الكحولیات في القسم رقم ۳. قد یؤثر عصیر جریب فروت على فعالیة عقار<br />كما یجب تناولھ بحذر. تحدث إلى طبیبك للحصول على المزید من المعلومات. &trade; ریكسوفیل<br />الخصوبة<br />قد لُوحظ انخفاض إنتاج الحیوانات المنویة في الاختبارات التي أجریت على الكلاب التي تم معالجتھا بھذا الدواء.<br />ولوحظ انخفاضًا في عدد الحیوانات المنویة لدى بعض الرجال. ومن غیر المحتمل أن تؤدي ھذه الآثار إلى قلة<br />الخصوبة.<br />القیادة واستخدام الآلات<br />بدوخة. ویجب أن تتأكد بعنایة &trade; أفادت التجارب السریریة إصابة بعض الرجال الذین یتناولون عقار ریكسوفیل<br />من تأثیر تناول الأقراص علیك قبل القیادة أو استخدام الآلات.<br />على سكر اللاكتوز: &trade; یحتوي عقار ریكسوفیل<br />إذا كنت لا تتحمل بعض أنواع السكریات، فاتصل بطبیبك قبل تناول ھذا العقار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدواء تمامًا حسب تعلیمات طبیبك. ویُرجى مراجعة طبیبك أو الصیدلي إذا لم تكن متأكدًا من<br />كیفیة التناول.<br />مخصصة للمرضى من الرجال فقط ویتم تناولھا عن طریق الفم. ابتلع القرص كاملًا بكوب &trade; أقراص ریكسوفیل<br />من الماء. یمكن تناول الأقراص مع الطعام أو بدونھ.<br />فتجنب ،&trade; شرب الكحول قد یؤدي إلى انخفاض مؤقت في ضغط الدم. إذا تناولت أو تنوي تناول عقار ریكسوفیل<br />الإفراط في تناول للكحولیات (مستوى الكحول بالدم ۰٫۰۸ ٪ أو أكثر) حیث قد یُؤدي الشرب المفرط للكحولیات<br />إلى ارتفاع خطر الإصابة بدوخة عند الوقوف.<br />لعلاج ضعف الانتصاب<br />الجرعة الموصى بھا ھي قرص واحد ٥ ملجم یؤخذ مرة واحدة یومیًا في نفس الوقت تقریبًا من الیوم. طبیبك قد<br />.&trade; یضبط الجرعة إلى ۲٫٥ ملجم على أساس استجابتك لعقار ریكسوفیل<br />أكثر من مرة واحدة یومیًا. &trade; لا تتناول عقار ریكسوفیل<br />مرة واحدة في الیوم ، فإنھ یسمح لك بالحصول على الانتصاب عند التحفیز &trade; عند تناول عقار ریكسوفیل<br />مرة واحدة في الیوم قد تكون مفیدة &trade; الجنسي في أي وقت خلال ال ۲٤ ساعة من الیوم. جرعة عقار ریكسوفیل<br />للرجال الذین یتوقعون ممارسة النشاط الجنسي مرتین أو أكثر في الأسبوع.<br />لن یكون فعالًا إذا لم یتم التحفیز الجنسي أولاً. سوف تحتاج أنت &trade; من المھم ملاحظة أن عقار ریكسوفیل<br />وزوجتك إلى ممارسة المداعبة تمامًا كما كنت تفعل في حالة عدم تناولك دواء لعلاج ضعف الانتصاب.<br />قد یُؤثر شرب الكحولیات على قدرتك على الانتصاب</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب ھذا الدواء، مثل كافة الأدویة، آثارًا جانبیة على الرغم من عدم حدوثھا لدى جمیع المرضى. وعادة ما<br />یتراوح المعدل الطبیعي لھذه الآثار بین الطفیفة والمتوسطة.<br />توقف عن تناول الدواء واطلب الرعایة الطبیة فورًا إذا تعرضت للإصابة بأي من ھذه الآثار الجانبیة التالیة:<br />- تفاعلات حساسیة بما في ذلك طفح جلدي (معدل التكرار غیر شائع).<br />- ألم بالصدر، لا تستخدم أدویة النترات واطلب الرعایة الطبیة فورًا (معدل التكرار: غیر شائع).<br />معدل التكرار: نادر). إذا عانیت من ) &trade; - انتصاب مستمر ومؤلم للقضیب &quot;قُسَاح&quot; بعد تناول عقار ریكسوفیل<br />ھذا الانتصاب، والذي یدوم لأكثر من ٤ ساعات متواصلة فیجب أن تتصل بطبیبك فورًا.<br />- فقدان مفاجئ للرؤیة (معدل التكرار: نادر).<br />تم الإبلاغ عن آثار جانبیة أخرى تشمل ما یلي:<br />آثار جانبیة شائعة (تحدث في مریض واحد من بین كل ۱۰۰ مریض):<br />- صداع، ألم بالظھر، وجع بالعضلات، ألم بالذراعین والساقین، احمرار الوجھ، احتقان الأنف وعسر الھضم.<br />آثار جانبیة غیر شائعة (تحدث في نسبة تتراوح من مریض واحد إلى ۱۰ مرضى من بین كل ۱٫۰۰۰<br />مریض):<br />- دوخة، ألم بالمعدة، شعور بإعیاء، إعیاء (قيء)، ارتجاع، عدم وضوح الرؤیة، ألم بالعین، صعوبة في التنفس،<br />اختلاط البول بالدم، انتصاب مستمر، إحساس بضربات قلب قویة، تسارع معدل ضربات القلب، ارتفاع ضغط<br />الدم، انخفاض ضغط الدم، نزیف بالأنف، رنین في الأذنین وتورم بالیدین أو القدمین أو الكاحلین وشعور بتعب.<br />آثار جانبیة نادرة (تحدث في نسبة تتراوح من مریض واحد إلى ۱۰ مرضى من بین كل ۱۰٫۰۰۰ مریض):<br />- إغماء، نوبات صرع وفقدان عابر للذاكرة، تورم الجفنین، احمرار العینین، انخفاض أو فقدان مفاجئ للسمع،<br />طفح جلدي (كدمات حمراء تسبب حكة على سطح الجلد)، نزیف بالعضو الذكري، مني مختلط بالدم وزیادة<br />إفراز العرق.<br />نادرًا ما تم الإبلاغ عن حدوث نوبة قلبیة وسكتة دماغیة في المرضى من الرجال الذین یتناولون عقار<br />كان معظم ھؤلاء الرجال یعانون من مشاكل بالقلب قبل تناول ھذا الدواء. .&trade; ریكسوفیل<br />نادرًا ما تم الإبلاغ عن فقدان جزئي أو مؤقت أو دائم في الرؤیة في إحدى العینین أو كلتیھما.<br />تم الإبلاغ عن بعض الآثار الجانبیة الإضافیة النادرة في المرضى من الرجال الذین یتناولون عقار<br />ولم تظھر في التجارب السریریة. &trade; ریكسوفیل<br />وتشمل ھذه الآثار الجانبیة ما یلي:<br />- صداع نصفي، تورم الوجھ، تفاعلات حساسیة خطیرة تسبب تورم في الوجھ أو الحنجرة، طفح جلدي خطیر،<br />بعض الاضطرابات التي تؤثر على تدفق الدم إلى العینین، عدم انتظام ضربات القلب، ذبحة صدریة والوفاة إثر<br />اضطرابات قلبیة مفاجئة.<br />تم الإبلاغ عن حدوث بعض الآثار الجانبیة مثل دوخة بمعدل تكرار أكبر في المرضى من الرجال الذین تزید<br />تم الإبلاغ عن زیادة معدل تكرار حدوث إسھال في .&trade; أعمارھم عن ۷٥ عامًا ویتناولون عقار ریكسوفیل<br />.&trade; المرضى من الرجال الذین تزید أعمارھم عن ٦٥ عامًا ویتناولون عقار ریكسوفیل<br />الإبلاغ عن الآثار الجانبیة<br />تحدَّث إلى طبیبك أو الصیدلي إذا أصبت بأیَّة آثار جانبیة. ویشمل ذلك أیة آثار جانبیة مُحتمَلة غیر مُدرجة في ھذه<br />النَّشرة. من خلال إبلاغك عن الآثار الجانبیة یمكنك المساعدة في توفیر معلومات إضافیة حول أمان استخدام ھذا<br />الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; یُحفظ بعیدًا عن متناول و مرأى الأطفال.<br />.&quot;EXP&quot; &bull; لا تستخدم ھذا الدواء بعد انتھاء تاریخ الصلاحیة المدوّن على العبوة الكرتونیة بعد كلمة<br />&bull; یُحفظ في العبوة الأصلیة وذلك لحمایتھ من الرطوبة.<br />&bull; یحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />&bull; لا تقمْ بالتخلص من الأدویة عن طریق إلقائھا في میاه الصرف أو مع المخلفات المنزلیة. استشر الصیدلي<br />الخاص بك حول كیفیة التَّخلص من الأدویة التي لم تعد بحاجة إلیھا. حیث تُساعد ھذه التدابیر في الحفاظ على<br />البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعالة ھي تادالافیل.<br />یحتوي كل قرص مغلّف على ٥ ملجم من تادالافیل.<br />- المكوّنات الأخرى ھي:<br />لاكتوز أحادي الھیدرات، ھیدروكسي بروبیل السلیلوز، كروس كارمیلوز الصودیوم، كبریتات صودیوم لوریل،<br />سلیلوز دقیق التبلور و ستیرات الماغنسیوم ، ھیبرومیلوز، ثاني أكسید التیتانیوم، تریاسیتین،<br />أكسید الحدید الأصفر غیر المشع و تلك.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">ما ھو شكل عقار ریكسوفیل&nbsp;&quot;JP&quot; ٥ ملجم أقراص مغلفة لونھا أصفر فاتح، بیضاویة الشكل، محفور على أحد جانبیھا &trade; عقار ریكسوفیل<br />.&quot; وعلى الجانب الآخر محفور &quot; 201</p><p style="text-align:right">یتوفر عقار ریكسوفیل&nbsp;في عبوات تحتوي على ۳۰ قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>شركة مصنع جمجوم للأدوية،</p><p>جدة، المملكة العربية السعودية.</p><p>&nbsp;هاتف: 6081111-12-966+</p><p>&nbsp;فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني www.jamjoompharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11-2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rexofil 5 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 5 mg of tadalfil
Excipients with known effect:
Each film-coated tablet contains 109 mg of lactose (as monohydrate)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Light yellow colored, almond shaped, film coated tablet, debossed with "201" on one side and "JP" on
the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult males.<br />In order for Tadalafil to be effective, sexual stimulation is required.<br />Tadalafil is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adult men<br />In general, the recommended dose is 10mg taken prior to anticipated sexual activity and with or without<br />food. In those patients in whom Tadalafil 10mg does not produce an adequate effect, 20mg might be<br />tried. It may be taken at least 30 minutes prior to sexual activity.<br />The maximum dose frequency is once per day.<br />Tadalafil 10mg and 20mg is intended for use prior to anticipated sexual activity and it is not<br />recommended for continuous daily use.<br />In patients who anticipate a frequent use of Tadalafil (i.e., at least twice weekly) a once daily regimen<br />with the lowest doses of Tadalafil might be considered suitable, based on patient choice and the<br />physician&#39;s judgement.<br />In these patients, the recommended dose is 5mg taken once a day at approximately the same time of day.<br />The dose may be decreased to 2.5mg once a day based on individual tolerability.<br />The appropriateness of continued use of the daily regimen should be reassessed periodically.<br />Special Populations<br />Elderly Men<br />Dose adjustments are not required in elderly patients.</p><p>Men with Renal Impairment<br />Dose adjustments are not required in patients with mild to moderate renal impairment. For patients with<br />severe renal impairment, 10mg is the maximum recommended dose. Once-a-day dosing of tadalafil is<br />not recommended in patients with severe renal impairment. (See sections 4.4 and 5.2.)<br />Men with Hepatic Impairment<br />The recommended dose of Tadalafil is 10mg taken prior to anticipated sexual activity and with or<br />without food. There is limited clinical data on the safety of Tadalafil in patients with severe hepatic<br />impairment (Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be<br />undertaken by the prescribing physician. There are no available data about the administration of doses<br />higher than 10mg of tadalafil to patients with hepatic impairment.<br />Once-a-day dosing has not been evaluated in patients with hepatic impairment; therefore if prescribed, a<br />careful individual benefit/risk evaluation should be undertaken by the prescribing physician. (See<br />sections 4.4 and 5.2.)<br />Men with Diabetes<br />Dose adjustments are not required in diabetic patients.<br />Paediatric population<br />There is no relevant use of Tadalafil in the paediatric population with regard to the treatment of erectile<br />dysfunction.<br />Method of administration<br />For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. In clinical
studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from
the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore,
administration of Tadalafil to patients who are using any form of organic nitrate is contraindicated. (See
section 4.5.)
Tadalafil, must not be used in men with cardiac disease for whom sexual activity is inadvisable.
Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing
cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical trials and the
use of tadalafil is therefore contraindicated:
• Patients with myocardial infarction within the last 90 days.
• Patients with unstable angina or angina occurring during sexual intercourse.
• Patients with New York Heart Association class 2 or greater heart failure in the last 6 months.
• Patients with uncontrolled arrhythmias, hypotension (<90/50mmHg), or uncontrolled hypertension.
• Patients with a stroke within the last 6 months.
Tadalafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic
anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or
not with previous PDE5 inhibitor exposure (see section 4.4).
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such
as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment with Tadalafil<br />A medical history and physical examination should be undertaken to diagnose erectile dysfunction and<br />determine potential underlying causes, before pharmacological treatment is considered.<br />Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular<br />status of their patients, since there is a degree of cardiac risk associated with sexual activity. Tadalafil<br />has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1),<br />and as such potentiates the hypotensive effect of nitrates (see section 4.3).<br />The evaluation of erectile dysfunction should include a determination of potential underlying causes and<br />the identification of appropriate treatment following an appropriate medical assessment. It is not known<br />if Tadalafil is effective in patients who have undergone pelvic surgery or radical non-nerve-sparing<br />prostatectomy.<br />Cardiovascular<br />Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable angina<br />pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain, palpitations and<br />tachycardia, have been reported either post marketing and/or in clinical trials. Most of the patients in<br />whom these events have been reported had pre-existing cardiovascular risk factors. However, it is not<br />possible to definitively determine whether these events are related directly to these risk factors, to<br />Tadalafil, to sexual activity, or to a combination of these or other factors.<br />In patients who are taking alpha1 blockers, concomitant administration of Tadalafil may lead to<br />symptomatic hypotension in some patients (see section 4.5). The combination of tadalafil and doxazosin<br />is not recommended.<br />Vision<br />Visual defects and cases of NAION have been reported in connection with the intake of Tadalafil and<br />other PDE5 inhibitors. Analyses of observational data suggest an increased risk of acute NAION in men<br />with erectile dysfunction following exposure to tadalafil or other PDE5 inhibitors. As this may be<br />relevant for all patients exposed to tadalafil, the patient should be advised that in case of sudden visual<br />defect, he should stop taking Tadalafil and consult a physician immediately (see section 4.3).</p><p>Decreased or sudden hearing loss<br />Cases of sudden hearing loss have been reported after the use of tadalafil. Although other risk factors<br />were present in some cases (such as age, diabetes, hypertension and previous hearing loss history)<br />patients should be advised to stop taking tadalafil and seek prompt medical attention in the event of<br />sudden decrease or loss of hearing.<br />Hepatic impairment<br />There is limited clinical data on the safety of single-dose administration of Tadalafil in patients with<br />severe hepatic insufficiency (Child-Pugh class C). If Tadalafil is prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician.<br />Priapism and anatomical deformation of the penis<br />Patients who experience erections lasting 4 hours or more should be instructed to seek immediate<br />medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of<br />potency may result.<br />Tadalafil, should be used with caution in patients with anatomical deformation of the penis (such as<br />angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have conditions which may<br />predispose them to priapism (such as sickle cell anaemia, multiple myeloma, or leukaemia).<br />Use with CYP3A4 inhibitors<br />Caution should be exercised when prescribing Tadalafil to patients using potent CYP3A4 inhibitors<br />(ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased tadalafil exposure<br />(AUC) has been observed if the medicinal products are combined (see section 4.5).<br />Tadalafil and other treatments for erectile dysfunction<br />The safety and efficacy of combinations of Tadalafil and other PDE5 inhibitors or other treatments for<br />erectile dysfunction have not been studied. The patients should be informed not to take Tadalafil in such<br />combinations.<br />Lactose<br />Tadalafil contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp<br />lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies were conducted with 10mg and/or 20mg tadalafil, as indicated below. With regard to<br />those interaction studies where only the 10mg tadalafil dose was used, clinically relevant interactions at<br />higher doses cannot be completely ruled out.<br />Effects of Other Substances on Tadalafil</p><p>Cytochrome P450 inhibitors<br />Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole<br />(200mg daily), increased tadalafil (10mg) exposure (AUC) 2-fold and Cmax by 15%, relative to the<br />AUC and Cmax values for tadalafil alone. Ketoconazole (400mg daily) increased tadalafil (20mg)<br />exposure (AUC) 4-fold and Cmax by 22%. Ritonavir, a protease inhibitor (200mg twice daily), which is<br />an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20mg) exposure<br />(AUC) 2-fold with no change in Cmax. Although specific interactions have not been studied, other<br />protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin,<br />clarithromycin, itraconazole, and grapefruit juice, should be co-administered with caution, as they would<br />be expected to increase plasma concentrations of tadalafil (see section 4.4). Consequently, the incidence<br />of the adverse reactions listed in section 4.8 might be increased.<br />Transporters<br />The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known.<br />Therefore, there is the potential of drug interactions mediated by inhibition of transporters.<br />Cytochrome P450 inducers<br />A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil<br />alone (10mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil; the<br />magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as phenobarbital,<br />phenytoin, and carbamazepine, may also decrease plasma concentrations of tadalafil.</p><p>Effects of Tadalafil on Other Medicinal Products<br />Nitrates<br />In clinical studies, tadalafil (5mg, 10mg and 20mg) was shown to augment the hypotensive effects of<br />nitrates. Therefore, administration of Tadalafil to patients who are using any form of organic nitrate is<br />contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects received<br />daily doses of tadalafil 20mg for 7 days and 0.4mg sublingual nitroglycerin at various times, this<br />interaction lasted for more than 24 hours and was no longer detectable when 48 hours had elapsed after<br />the last tadalafil dose. Thus, in a patient prescribed any dose of Tadalafil (2.5mg - 20mg), where nitrate<br />administration is deemed medically necessary in a life-threatening situation, at least 48 hours should<br />have elapsed after the last dose of Tadalafil before nitrate administration is considered. In such<br />circumstances, nitrates should only be administered under close medical supervision with appropriate<br />haemodynamic monitoring.<br />Anti-hypertensives (including calcium channel blockers)<br />The co-administration of doxazosin (4 and 8mg daily) and tadalafil (5mg daily dose and 20mg as a<br />single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.<br />This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore, this<br />combination is not recommended (see section 4.4).<br />In interaction studies performed in a limited number of healthy volunteers, these effects were not<br />reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in&nbsp;patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at<br />minimal dosage and progressively adjusted.<br />In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of<br />antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal<br />products were studied, including calcium-channel blockers (amlodipine), angiotensin converting enzyme<br />(ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics<br />(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in combination<br />with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10mg, except<br />for studies with angiotensin II receptor blockers and amlodipine in which a 20mg dose was applied) had<br />no clinically significant interaction with any of these classes. In another clinical pharmacology study,<br />tadalafil (20mg) was studied in combination with up to 4 classes of antihypertensives. In subjects taking<br />multiple antihypertensives, the ambulatory-blood-pressure changes appeared to relate to the degree of<br />blood pressure control. In this regard, study subjects whose blood pressure was well controlled, the<br />reduction was minimal and similar to that seen in healthy subjects. In study subjects whose blood<br />pressure was not controlled, the reduction was greater, although this reduction was not associated with<br />hypotensive symptoms in the majority of subjects. In patients receiving concomitant antihypertensive<br />medicinal products, tadalafil 20mg may induce a blood pressure decrease, which (with the exception of<br />alpha-blockers - see above) is, in general, minor and not likely to be clinically relevant. Analysis of<br />Phase 3 clinical trial data showed no difference in adverse events in patients taking tadalafil with or<br />without antihypertensive medicinal products. However, appropriate clinical advice should be given to<br />patients regarding a possible decrease in blood pressure when they are treated with antihypertensive<br />medicinal products.<br />Riociguat<br />Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors<br />were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive<br />effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the<br />population studied. Concomitant use of riociguat with PDE5 inhibitors, including tadalafil, is<br />contraindicated (see section 4.3).<br />5- alpha reductase inhibitors<br />In a clinical trial that compared tadalafil 5 mg coadministered with finasteride 5 mg to placebo plus<br />finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were identified. However, as<br />a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha reductase inhibitors<br />(5-ARIs) has not been performed, caution should be exercised when tadalafil is co-administered with 5-<br />ARIs.</p><p>CYP1A2 substrates (e.g. theophylline)<br />When tadalafil 10mg was administered with theophylline (a non-selective phosphodiesterase inhibitor)<br />in a clinical pharmacology study, there was no pharmacokinetic interaction. The only pharmacodynamic<br />effect was a small (3.5 bpm) increase in heart rate. Although this effect is minor and was of no clinical<br />significance in this study, it should be considered when co-administering these medicinal products.</p><p>Ethinylestradiol and terbutaline<br />Tadalafil has been demonstrated to produce an increase in the oral bioavailability of ethinylestradiol; a<br />similar increase may be expected with oral administration of terbutaline, although the clinical<br />consequence of this is uncertain.<br />Alcohol<br />Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by coadministration<br />with tadalafil (10mg or 20mg). In addition, no changes in tadalafil concentrations were<br />seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to maximise<br />the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol). Tadalafil (20mg)<br />did not augment the mean blood pressure decrease produced by alcohol (0.7g/kg or approximately<br />180ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects, postural dizziness and orthostatic<br />hypotension were observed. When tadalafil was administered with lower doses of alcohol (0.6g/kg),<br />hypotension was not observed and dizziness occurred with similar frequency to alcohol alone. The effect<br />of alcohol on cognitive function was not augmented by tadalafil (10mg).<br />Cytochrome P450 metabolised medicinal products<br />Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of<br />medicinal products metabolised by CYP450 isoforms. Studies have confirmed that tadalafil does not<br />inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and<br />CYP2C19.<br />CYP2C9 substrates (e.g. R-warfarin)<br />Tadalafil (10mg and 20mg) had no clinically significant effect on exposure (AUC) to S-warfarin or Rwarfarin<br />(CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by warfarin.<br />Aspirin<br />Tadalafil (10mg and 20mg) did not potentiate the increase in bleeding time caused by acetylsalicylic<br />acid.<br />Antidiabetic medicinal products<br />Specific interaction studies with antidiabetic medicinal products were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tadalafil is not indicated for use by women.<br />Pregnancy<br />There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate direct<br />or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or<br />postnatal development (see section 5.3). As a precautionary measure, it is preferable to avoid the use of<br />Tadalafil during pregnancy.</p><p>Breastfeeding<br />Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in milk. A<br />risk to the suckling child cannot be excluded. Tadalafil should not be used during breast feeding.<br />Fertility<br />Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical studies<br />suggest that this effect is unlikely in humans, although a decrease in sperm concentration was seen in<br />some men (see sections 5.1 and 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tadalafil has negligible influence on the ability to drive or use machines. Although the frequency of<br />reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be aware<br />of how they react to Tadalafil before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most commonly reported adverse reactions in patients taking Tadalafil for the treatment of erectile<br />dysfunction were headache, dyspepsia, back pain and myalgia, in which the incidences increase with<br />increasing dose of Tadalafil. The adverse reactions reported were transient, and generally mild or<br />moderate. The majority of headaches reported with Tadalafil once-a-day dosing are experienced within<br />the first 10 to 30 days of starting treatment.<br />Tabulated list of adverse reactions<br />The table below lists the adverse reactions observed from spontaneous reporting and in placebocontrolled<br />clinical trials (comprising a total of 8022 patients on Tadalafil and 4422 patients on placebo)<br />for on-demand and once-a-day treatment of erectile dysfunction.<br />Frequency convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to<br />&lt;1/100), rare (&ge;1/10,000 to &lt;1/1000), very rare (&lt;1/10,000) and not known (cannot be estimated from<br />the available data).</p><p>2 Postmarketing surveillance reported adverse reactions not observed in placebo-controlled clinical<br />trials.<br />3 More commonly reported when tadalafil is given to patients who are already taking antihypertensive<br />medicinal products.<br />Description of selected adverse reactions<br />A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported in<br />patients treated with tadalafil once a day as compared with placebo. Most of these ECG abnormalities<br />were not associated with adverse reactions.<br />Other special populations<br />Data in patients over 65 years of age receiving tadalafil in clinical trials for the treatment of erectile<br />dysfunction are limited. In clinical trials with tadalafil taken on demand for the treatment of erectile<br />dysfunction, diarrhoea was reported more frequently in patients over 65 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of up to 500mg have been given to healthy subjects, and multiple daily doses up to 100mg<br />have been given to patients. Adverse events were similar to those seen at lower doses. In cases of<br />overdose, standard supportive measures should be adopted, as required. Haemodialysis contributes<br />negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals, drugs used in erectile dysfunction, ATC code: G04BE08.<br />Mechanism of action<br />Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific<br />phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide,<br />inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This<br />results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an<br />erection. Tadalafil has no effect in the absence of sexual stimulation.</p><p>Pharmacodynamic effects<br />Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in<br />corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal muscle, platelets,<br />kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5 than on other<br />phosphodiesterases. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4,<br />enzymes which are found in the heart, brain, blood vessels, liver, and other organs. Tadalafil is &gt;10,000-<br />fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. This<br />selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved in cardiac<br />contractility. Additionally, tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an<br />enzyme which is found in the retina and is responsible for phototransduction. Tadalafil is also &gt;10,000-<br />fold more potent for PDE5 than for PDE7 through PDE10.<br />Clinical efficacy and safety<br />Three clinical studies were conducted in 1054 patients in an at-home setting to define the period of<br />responsiveness to Tadalafil. Tadalafil demonstrated statistically significant improvement in erectile<br />function and the ability to have successful sexual intercourse up to 36 hours following dosing, as well as<br />patients&#39; ability to attain and maintain erections for successful intercourse compared to placebo as early<br />as 16 minutes following dosing.<br />Tadalafil administered to healthy subjects produced no significant difference compared to placebo in<br />supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8mmHg, respectively), in<br />standing systolic and diastolic blood pressure (mean maximal decrease of 0.2/4.6mmHg, respectively),<br />and no significant change in heart rate.<br />In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination<br />(blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent with the<br />low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical studies, reports of changes in<br />colour vision were rare (&lt;0.1%).<br />Three studies were conducted in men to assess the potential effect on spermatogenesis of Tadalafil 10mg<br />(one 6-month study) and 20mg (one 6-month and one 9-month study) administered daily. In two of these<br />studies decreases were observed in sperm count and concentration related to tadalafil treatment of<br />unlikely clinical relevance. These effects were not associated with changes in other parameters, such as<br />motility, morphology, and FSH.<br />Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250 patients,<br />including patients with erectile dysfunction of various severities (mild, moderate, severe), etiologies,<br />ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction of at least 1 year in<br />duration. In the primary efficacy studies of general populations, 81% of patients reported that Tadalafil<br />improved their erections as compared to 35% with placebo. Also, patients with erectile dysfunction in<br />all severity categories reported improved erections whilst taking Tadalafil (86%, 83%, and 72% for<br />mild, moderate, and severe, respectively, as compared to 45%, 42%, and 19% with placebo). In the<br />primary efficacy studies, 75% of intercourse attempts were successful in Tadalafil -treated patients as<br />compared to 32% with placebo.<br />In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile dysfunction<br />secondary to spinal cord injury, tadalafil significantly improved the erectile function leading to a mean<br />per-subject proportion of successful attempts in patients treated with tadalafil 10 or 20 mg (flexibledose,<br />on demand) of 48% as compared to 17% with placebo.</p><p>Paediatric population<br />A single study has been performed in paediatric patients with Duchenne Muscular Dystrophy (DMD) in<br />which no evidence of efficacy was seen. The randomised, double-blind, placebo-controlled, parallel, 3-<br />arm study of tadalafil was conducted in 331 boys aged 7-14 years with DMD receiving concurrent<br />corticosteroid therapy. The study included a 48-week double-blind period where patients were<br />randomised to tadalafil 0.3 mg/kg, tadalafil 0.6 mg/kg, or placebo daily. Tadalafil did not show efficacy<br />in slowing the decline in ambulation as measured by the primary 6 minute walk distance (6MWD)<br />endpoint: least squares (LS) mean change in 6MWD at 48 weeks was -51.0 meters (m) in the placebo<br />group, compared with -64.7 m in the tadalafil 0.3 mg/kg group (p = 0.307) and -59.1 m in the tadalafil<br />0.6 mg/kg group (p = 0.538). In addition, there was no evidence of efficacy from any of the secondary<br />analyses performed in this study. The overall safety results from this study were generally consistent<br />with the known safety profile of tadalafil and with adverse events (AEs) expected in a paediatric DMD<br />population receiving corticosteroids.<br />The European Medicines Agency has waived the obligation to submit the results of studies in all subsets<br />of the paediatric population in the treatment of the erectile dysfunction. See section 4.2 for information<br />on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma<br />concentration (Cmax) is achieved at a median time of 2 hours after dosing. Absolute bioavailability of<br />tadalafil following oral dosing has not been determined. The rate and extent of absorption of tadalafil are<br />not influenced by food, this tadalafil may be taken with or without food. The time of dosing (morning<br />versus evening) had no clinically relevant effects on the rate and extent of absorption.<br />Distribution<br />The mean volume of distribution is approximately 63l, indicating that Tadalafil is distributed into<br />tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound in proteins. Protein binding is<br />not affected by impaired renal function. Less than 0.0005% of the administered dose appeared in the<br />semen of healthy subjects.<br />Biotransformation<br />Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major<br />circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold less<br />potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at observed<br />metabolite concentrations.<br />Elimination<br />The mean oral clearance for tadalafil is 2.5l/h and the mean half-life is 17.5 hours in healthy subjects.<br />Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately 61% of<br />the dose) and to a lesser extent in the urine (approximately 36% of the dose).<br />Linearity/non-linearity<br />Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a dose<br />range of 2.5 to 20mg, exposure (AUC) increases proportionally with dose. Steady-state plasma<br />concentrations are attained within 5 days of once-daily dosing.</p><p>Pharmacokinetics determined with a population approach in patients with erectile dysfunction are<br />similar to pharmacokinetics in subjects without erectile dysfunction.<br />Other special populations<br />Elderly<br />Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in 25%<br />higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is not<br />clinically significant and does not warrant a dose adjustment.<br />Renal impairment<br />In clinical pharmacology studies using single dose tadalafil (5mg-20mg), tadalafil exposure (AUC)<br />approximately doubled in subjects with mild (creatinine clearance 51 to 80ml/min) or moderate<br />(creatinine clearance 31 to 50ml/min) renal impairment and in subjects with end-stage renal disease on<br />dialysis. In haemodialysis patients, Cmax was 41% higher than that observed in healthy subjects.<br />Haemodialysis contributes negligibly to tadalafil elimination.<br />Hepatic Insufficiency<br />Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh class A<br />and B) is comparable to exposure in healthy subjects when a dose of 10mg is administered. There is<br />limited clinical data on the safety of Tadalafil in patients with severe hepatic insufficiency (Child-Pugh<br />class C). If Tadalafil is prescribed, a careful individual benefit/risk evaluation should be undertaken by<br />the prescribing physician. There are no available data about the administration of doses higher than<br />10mg of tadalafil to patients with hepatic impairment.<br />Patients with diabetes<br />Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value<br />for healthy subjects. This difference in exposure does not warrant a dose adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.<br />There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that received up<br />to 1000mg/kg/day tadalafil. In a rat prenatal and postnatal development study, the no observed effect<br />dose was 30mg/kg/day. In the pregnant rat the AUC for calculated free drug at this dose was<br />approximately 18-times the human AUC at a 20mg dose.<br />There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for 6 to 12<br />months at doses of 25mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-18.6] than<br />seen in humans given a single 20mg dose) and above, there was regression of the seminiferous tubular<br />epithelium that resulted in a decrease in spermatogenesis in some dogs. See also section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate<br />Hydroxypropyl Cellulose<br />Croscarmellose Sodium<br />Sodium Lauryl Sulphate<br />Microcrystalline cellulose<br />Magnesium Stearate<br />Hypromellose<br />Titanium dioxide<br />Triacetin<br />Yellow iron oxide-non irradiated<br />Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg; C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary Packaging: Alu-PVC/Aclar blister.<br />Secondary Packaging: Carton and PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>